Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 2
2007 1
2009 1
2010 3
2011 1
2012 2
2013 1
2014 1
2015 3
2016 2
2017 1
2018 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
ALSFRS-R.
Gordon PH, Miller RG, Moore DH. Gordon PH, et al. Among authors: moore dh. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:90-3. doi: 10.1080/17434470410019906. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512883 Review.
The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimizes dropout, reduces cost, and correlates with survival. Unlike the other standard outcome measures currently employed, the ALSFRS-R is …
The ALSFRS-R is an attractive primary outcome measure in clinical trials of ALS because it is validated, easy to administer, minimize …
Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM, Moore DH, Bedlack RS. Pastula DM, et al. Among authors: moore dh. Cochrane Database Syst Rev. 2012 Dec 12;12:CD005225. doi: 10.1002/14651858.CD005225.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235621 Review.
Our primary outcome was tracheostomy-free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional rating revised scores (ALSFRS-R) and per cent predicted forced vital capacity (FVC) over time. ...Using a pooled log-rank statistical t …
Our primary outcome was tracheostomy-free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional ra …
Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM, Moore DH, Bedlack RS. Pastula DM, et al. Among authors: moore dh. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD005225. doi: 10.1002/14651858.CD005225.pub2. Cochrane Database Syst Rev. 2010. PMID: 20556761 Updated. Review.
Our primary outcome was tracheostomy-free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional rating revised scores (ALSFRS-R) and percent predicted forced vital capacity (FVC) over time. ...Using a pooled log-rank statistical te …
Our primary outcome was tracheostomy-free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional ra …
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.
Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. Berry JD, et al. Among authors: moore dh. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8. doi: 10.3109/21678421.2012.762930. Epub 2013 Jan 17. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23323713 Review.
CAFS ranks patients' clinical outcomes based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Each patient's outcome is compared to every other patient's outcome, assigned a score, and the summed scores are ranked. ...
CAFS ranks patients' clinical outcomes based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. …
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.
Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Statland JM, et al. Among authors: moore d. Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26. Muscle Nerve. 2019. PMID: 30192007 Free PMC article. Clinical Trial.
The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. RESULTS: There was no difference in the a …
The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included s …
Prognostic categories for amyotrophic lateral sclerosis.
Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Janssen A, Nigro C, Sakel M, Leigh PN, Shaw C, Al-Chalabi A. Scotton WJ, et al. Among authors: moore dh. Amyotroph Lateral Scler. 2012 Oct;13(6):502-8. doi: 10.3109/17482968.2012.679281. Epub 2012 Jun 7. Amyotroph Lateral Scler. 2012. PMID: 22670880
A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r(2) = 0.72). Six variables were included in the survival model: age at onset, diagnostic delay, El Escorial category, use of riluzole, gender and site of onset. .. …
A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r(2) = 0.72). Six variab …
Phase I clinical trial of safety of L-serine for ALS patients.
Levine TD, Miller RG, Bradley WG, Moore DH, Saperstein DS, Flynn LE, Katz JS, Forshew DA, Metcalf JS, Banack SA, Cox PA. Levine TD, et al. Among authors: moore dh. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):107-111. doi: 10.1080/21678421.2016.1221971. Epub 2016 Sep 2. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 27589995 Clinical Trial.
Blood, urine and CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores and forced vital capacity (FVC) were obtained throughout the trial. ...L-serine was generally well tolerated by the patients and L-serine did not appear to accelerate functional decline of …
Blood, urine and CSF samples, ALS Functional Rating Scale-Revised (ALSFRS-R) scores and forced vital capacity (FVC) were obtained thr …
Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC. Eppenberger-Castori S, et al. Among authors: moore dh jr. Int J Biochem Cell Biol. 2002 Nov;34(11):1318-30. doi: 10.1016/s1357-2725(02)00052-3. Int J Biochem Cell Biol. 2002. PMID: 12200028
No biomarker reflecting tumor angiogenic, invasive or proteolytic potential showed a significant correlation with patient age at diagnosis. In contrast, significant inverse correlations (|r|>0.1; P< or =0.05) were observed for all measures of tumor growth and genetic …
No biomarker reflecting tumor angiogenic, invasive or proteolytic potential showed a significant correlation with patient age at diagnosis. …
Phrenic nerve conduction studies as a biomarker of respiratory insufficiency in amyotrophic lateral sclerosis.
Jenkins JA, Sakamuri S, Katz JS, Forshew DA, Guion L, Moore D, Miller RG. Jenkins JA, et al. Among authors: moore d. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):213-20. doi: 10.3109/21678421.2015.1112406. Epub 2015 Nov 30. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 26618854
We prospectively recorded bilateral PNCS, forced vital capacity (FVC), maximum inspiratory pressure (MIP), sniff nasal inspiratory pressure (SNIP), respiratory rate, ALSFRS-R, and respiratory symptoms in 100 ALS patients attending our clinic over a nine-month period. ...Si …
We prospectively recorded bilateral PNCS, forced vital capacity (FVC), maximum inspiratory pressure (MIP), sniff nasal inspiratory pressure …
20 results